Spero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed by a Portion of Utebzi Milestones & Royalties

Rhea-AI Summary

Spero Therapeutics (Nasdaq: SPRO) announced a $105 million non-recourse, non-dilutive royalty financing with affiliates of Healthcare Royalty (HCRx), a business of KKR, backed by a portion of future Utebzi (tebipenem pivoxil) milestones and royalties from GSK.

According to Spero, proceeds will primarily fund Phase 2 development of SP001, a Phase 2-ready, Fc-silent, third-generation anti-CD40L monoclonal antibody for immune-mediated diseases, in-licensed from Innovent Biologics under an exclusive agreement signed concurrently with the financing. HCRx will receive quarterly principal and interest payments derived solely from GSK payments owed to Spero until the loan is repaid, after which Spero will retain 35% of subsequent GSK Utebzi milestone and royalty payments. Spero also updated its cash runway guidance into the second half of 2029.

Positive

• $105 million non-recourse, non-dilutive royalty financing secured at closing
• Financing extends Spero’s cash runway into 2H 2029
• Proceeds directed to Phase 2 development of lead asset SP001
• Spero retains 35% of GSK Utebzi payments after loan repayment
• Concurrent exclusive license secured for SP001 from Innovent Biologics

Negative

• Spero assigns a majority of future GSK Utebzi payments, retaining only 35% after repayment
• Future Utebzi milestones and royalties must service quarterly principal and interest on the HCRx loan

News Explained

The July 14 release states that the royalty financing and SP001 license were completed concurrently, so this is an executed transaction rather than only a proposed funding arrangement; Spero receives the payment at closing while HCRx receives future Utebzi-linked payments.

News Market Reaction – SPRO

-17.92% 5.5x vol

52 alerts

-17.92% News Effect

+6.5% Peak Tracked

-32.5% Trough Tracked

-$28M Valuation Impact

$126.23M Market Cap

5.5x Rel. Volume

On the day this news was published, SPRO declined 17.92%, reflecting a significant negative market reaction. Argus tracked a peak move of +6.5% during that session. Argus tracked a trough of -32.5% from its starting point during tracking. Our momentum scanner triggered 52 alerts that day, indicating high trading interest and price volatility. This price movement removed approximately $28M from the company's valuation, bringing the market cap to $126.23M at that time. Trading volume was exceptionally heavy at 5.5x the daily average, suggesting significant selling pressure.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock dropped -17.9% in the session following this news. A sharp decline after this announcement...

Analysis

The stock dropped -17.9% in the session following this news. A sharp decline after this announcement would contrast with the ostensibly supportive $105 million financing and longer runway into 2029, echoing past divergence like the post-approval drop. With low short interest, downside would more likely reflect concerns around future capital needs or prior insider selling.

Key Figures

Royalty financing size: $105 million Cash runway: Second half of 2029 Retained GSK payments: 35% +1 more

4 metrics

Royalty financing size $105 million Non-recourse, non-dilutive financing with HCRx

Cash runway Second half of 2029 Updated cash runway guidance post-transaction

Retained GSK payments 35% Portion of Utebzi-related GSK payments Spero keeps after loan repaid

Development stage Phase 2-ready SP001 immunology candidate

Historical Context

5 past events · Latest: Jun 17 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jun 17	FDA approval	Positive	-23.8%	Utebzi received US FDA approval for complicated urinary tract infections.
May 28	Board change	Neutral	-1.0%	Compass Pathways elected Kathleen Tregoning to its Board of Directors.
May 13	Quarterly earnings	Positive	+13.1%	Q1 2026 results showed reduced net loss and reiterated cash runway into 2028.
May 05	Earnings date	Neutral	+4.5%	Company scheduled release of Q1 2026 financial results and business update.
Mar 26	Full-year earnings	Positive	-1.7%	Reported 2025 profitability, higher revenue, and cash runway guidance into 2028.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent Spero news has shown mixed reactions, with FDA approval and a strong earnings report producing opposite share-price moves.

Key Terms

non-recourse, non-dilutive, royalty financing, monoclonal antibody, +1 more

5 terms

non-recourse financial

"announced a $105 million non-recourse non-dilutive royalty financing transaction"

A non-recourse loan is a type of debt where the lender’s recovery is limited to a specific asset pledged as collateral, and the borrower cannot be personally pursued for any remaining balance if the asset’s value falls short. For investors, non-recourse financing shifts downside risk onto the lender and protects a borrower’s other assets, which can affect a company’s risk profile, borrowing costs, and potential returns — much like insurance that covers only the item left as collateral.

non-dilutive financial

"announced a $105 million non-recourse non-dilutive royalty financing transaction"

Non-dilutive describes funding or income that does not reduce existing shareholders’ ownership percentage. It matters to investors because it lets a company raise money or generate value—through grants, loans, licensing deals, or revenue—without issuing extra shares, so each existing share keeps the same claim on profits and control; think of adding toppings to a cake without cutting it into more slices.

royalty financing financial

"non-recourse non-dilutive royalty financing transaction with affiliates of Healthcare Royalty"

Royalty financing is a way for a business to raise money by selling a share of future revenue or product sales in exchange for upfront cash; the investor is paid back as the company earns money, like buying a claim on a slice of each future sale. It matters to investors because returns depend on the company’s actual sales rather than its profits or stock price, offering potential steady income if products perform well but carrying risk if revenue falls short.

monoclonal antibody medical

"SP001, a Phase 2-ready, Fc-silent, third-generation anti-CD40L monoclonal antibody"

A monoclonal antibody is a laboratory-made protein designed to recognize and attach to a specific target in the body, such as a disease-causing substance or cell. It functions like a highly precise lock-and-key tool, helping to treat or detect illnesses. For investors, companies developing monoclonal antibodies can represent promising opportunities in the healthcare sector, especially as these treatments often address unmet medical needs.

original issue discount financial

"payment at closing, net of original issue discount and applicable fees"

Original issue discount (OID) is the difference between a debt security’s face value and the lower price at which it is first sold, treated as additional interest that accrues over the life of the instrument. For investors it matters because OID raises the effective yield and changes taxable income and the holding’s cost basis over time — think of buying a $100 voucher for $90 and recognizing the $10 gain as earned interest as the voucher approaches maturity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• Financing supports Phase 2 development of SP001, Spero’s first immunology drug candidate, in-licensed from Innovent Biologics
• Transaction unlocks immediate value from future Utebzi (tebipenem pivoxil) milestones and royalties, and positions Spero to participate in potential long-term commercial upside
• Spero updates its cash runway guidance into the second half of 2029
  

CAMBRIDGE, Mass., July 14, 2026 (GLOBE NEWSWIRE) --  Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, today announced a $105 million non-recourse non-dilutive royalty financing transaction with affiliates of Healthcare Royalty, a business of KKR (HCRx). Under the agreement, HCRx will receive a portion of future milestone and royalty payments associated with sales of Utebzi™ (tebipenem pivoxil). The proceeds will primarily be used to support advancement of Spero’s lead immunology drug candidate, SP001, a Phase 2-ready, Fc-silent, third-generation anti-CD40L monoclonal antibody with potential for development across a range of immune-mediated diseases.

"Over the past year, in collaboration with GSK, we successfully advanced Utebzi through FDA approval, while executing on our strategy to strengthen Spero and position the Company for its next phase of growth. This transaction further strengthens our balance sheet and provides non-dilutive capital as we embark on an immunology-focused strategy,” said Esther Rajavelu, President and Chief Executive Officer of Spero Therapeutics. "By unlocking immediate value from a portion of future Utebzi milestone and royalty streams, we are well positioned to execute on the clinical development for SP001 and continue building a differentiated pipeline for patients with immune-mediated diseases.”

The financing was completed concurrently with the execution of an exclusive license agreement with Innovent Biologics for the SP001 asset and follows last month's U.S. approval of Spero Therapeutics-developed Utebzi for complicated urinary tract infections. Spero Therapeutics has granted GSK an exclusive license to develop and commercialize Utebzi in all territories, except certain territories in Asia, where Meiji holds development and commercialization rights. Following the transaction, Spero updates its cash runway guidance into the second half of 2029.

“We are pleased to partner with Spero on this acquisition of certain Utebzi milestones and royalties. As the first approved oral carbapenem therapy, Utebzi represents a meaningful innovation and value proposition for patients, physicians and payers,” said Clarke Futch, Chairman and CEO of HealthCare Royalty.

Terms of the Agreement
Under the terms of the agreements, HCRx will provide Spero with a $105 million payment at closing, net of original issue discount and applicable fees, in exchange for rights to anticipated payments from sales of Utebzi owing from GSK. HCRx will receive quarterly principal and interest payments, derived solely from the GSK payments due to Spero, until the loan balance is repaid. Following repayment, Spero will retain 35% of subsequent GSK payments related to sales of Utebzi, preserving potential long-term upside from the asset.

J. Wood Capital Advisors acted as Spero’s exclusive financial adviser and WilmerHale acted as legal advisor to Spero on the financing transaction. Sidley Austin LLP acted as legal advisor to HCRx.

About SP001
SP001 is a third-generation, fully humanized, Fc-silent IgG1 monoclonal antibody targeting CD40L, an upstream immune activation signal involved in T-cell, B-cell, antigen-presenting cell, and platelet biology. By blocking CD40L, SP001 has the potential to provide a targeted non-B-cell-depleting treatment across multiple immune-mediated diseases where immune-cell interactions drive chronic inflammation, relapse, and tissue damage. SP001 is designed to address platelet activation concerns associated with earlier anti-CD40L antibodies, while preserving key monoclonal antibody properties, including FcRn interaction that supports IgG-like half-life.

About HealthCare Royalty
HealthCare Royalty (“HCRx”) is a leading royalty acquisition company founded in 2006 that is majority owned by KKR & Co. Inc. (NYSE: KKR). Over two decades, the HCRx team has developed a strong track record of investing in commercial-stage and near-commercial-stage biopharmaceutical assets, committing $7+ billion in over 110 biopharmaceutical products. With offices in New York, Stamford, San Francisco, Boston, London and Miami, HCRx continues to advance biopharmaceutical innovation by providing innovative capital solutions to counterparties. For more information, visit https://www.hcrx.com. HEALTHCARE ROYALTY^®, HEALTHCARE ROYALTY PARTNERS^® and HCRx^® are registered trademarks of HealthCare Royalty Management, LLC.

About Spero Therapeutics
Spero Therapeutics is a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation for patients with serious diseases and major treatment gaps. The company’s lead program, SP001, is a third-generation, Fc-silent anti-CD40L monoclonal antibody being advanced first in IgG4-related disease, with a broad potential for additional immune-related conditions. For more information, visit SperoTx.com

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements include, but are not limited to, statements relating to the anticipated benefits of the non-dilutive royalty-backed transaction, including the anticipated use of proceeds; Spero’s expectations regarding its ability to advance SP001 into clinical development and the potential benefits thereof; anticipated cash runway, and future milestones; and the potential benefits of Spero’s agreement with Innovent. Forward-looking statements are based on Spero’s current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, among others, risks related to the completion and integration of the Innovent transaction; Spero’s ability to successfully develop SP001; the timing and outcome of clinical trials and regulatory interactions; the ability to obtain and maintain regulatory approvals; potential safety, efficacy, manufacturing, supply, intellectual property, financing, competitive, and market risks; and other risks described in Spero’s filings with the Securities and Exchange Commission. Spero undertakes no obligation to update any forward-looking statements, except as required by law.

Investor Relations Contact:
Shai Biran, PhD
Spero Therapeutics
IR@Sperotherapeutics.com

Media Inquiries:
media@sperotherapeutics.com

FAQ

What is the size and structure of Spero Therapeutics’ (SPRO) July 2026 financing?

Spero Therapeutics secured a $105 million non-recourse, non-dilutive royalty financing from HCRx. According to Spero, HCRx receives rights to Utebzi-related milestone and royalty payments from GSK, with principal and interest repaid solely from these GSK payment streams.

How will Spero Therapeutics use the $105 million financing for SP001?

Spero plans to use the proceeds primarily to advance SP001 into Phase 2 clinical development. According to Spero, SP001 is a Phase 2-ready, Fc-silent, third-generation anti-CD40L monoclonal antibody targeting multiple immune-mediated diseases.

How does the Utebzi royalty financing affect Spero Therapeutics’ future GSK payments?

HCRx will receive quarterly principal and interest payments derived solely from Utebzi payments owed by GSK to Spero. According to Spero, once the loan is repaid, Spero will retain 35% of subsequent GSK milestone and royalty payments from Utebzi sales.

What does the $105 million financing mean for Spero Therapeutics’ (SPRO) cash runway?

The financing allows Spero to extend its cash runway into the second half of 2029. According to Spero, this longer runway supports execution of its immunology-focused strategy and the planned clinical development of SP001 and broader pipeline activities.

What is the relationship between Spero Therapeutics, GSK, and Utebzi royalties?

Spero granted GSK an exclusive license to develop and commercialize Utebzi globally, except certain Asian territories held by Meiji. According to Spero, the HCRx financing is backed by milestone and royalty payments owed from GSK’s Utebzi sales to Spero.

What recent regulatory milestone supports Spero Therapeutics’ Utebzi royalty deal?

The financing follows U.S. approval of Utebzi for complicated urinary tract infections in the prior month. According to Spero, this first approved oral carbapenem therapy underpins the value of future Utebzi milestones and royalties supporting the HCRx financing.